Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.41 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL834353 | 1.00 | MMP2 (0.50) | MMP2MMP7MMP14CYP2C19HSD11B1 | |
| SCHEMBL12750892 | 0.79 | KMT2A (0.58) | CYP2C19HSD11B1TSHRSMN1; SMN2KMT2A | |
| SCHEMBL270706 | 0.77 | MMP2 (0.77) | MMP2MMP7MMP14HSD11B1SMN1; SMN2 | |
| SCHEMBL6552547 | 0.76 | MMP2 (0.74) | MMP2MMP7MMP14HSD11B1SMN1; SMN2 | |
| SCHEMBL6552246 | 0.76 | MMP2 (0.74) | MMP2MMP7MMP14HSD11B1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL20473391 | 0.76 | MMP2 (0.74) | MMP2MMP7MMP14HSD11B1SMN1; SMN2 | |
| SCHEMBL6553661 | 0.76 | MMP2 (0.74) | MMP2MMP7MMP14HSD11B1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL20473392 | 0.76 | MMP2 (0.74) | MMP2MMP7MMP14HSD11B1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL8418478 | 0.76 | MMP2 (0.74) | MMP2MMP7MMP14HSD11B1SMN1; SMN2 | |
| SCHEMBL6553421 | 0.76 | MMP2 (0.74) | MMP2MMP7MMP14HSD11B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099757-B1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8383825-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120207810-A1 | Kinase Inhibitors | SPADA LON T (US) | 2012-08-16 | — | — | US | disclosed |
| US-8143410-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110263611-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2011-10-27 | — | — | US | disclosed |
| WO-2010078393-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-2099757-A2 | SULFOXIMINES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090196906-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2008061236-A2 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263611-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | MMP2 1207/4885MMP7 1366/4885MMP14 1554/4885 |
| US-20120207810-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | MMP2 1207/4885MMP7 1366/4885MMP14 1554/4885 |
| US-20090196906-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | MMP2 1207/4885MMP7 1366/4885MMP14 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.